Bloomberg New Economy
International Cancer Coalition
Our mission
The Bloomberg New Economy International Cancer Coalition is a multistakeholder platform, bringing together leading figures from academia, industry, government, patient advocacy, and policy organizations to accelerate the development of cancer cures and prevention on a global scale.
Founded in 2021, the Coalition’s mission is to strengthen international clinical trial collaboration and improve patient access to cutting-edge treatments, while promoting regulatory cooperation worldwide to speed up approvals of new therapies, diagnostics, and preventive measures. Ultimately, the Coalition strives to save millions of lives by bringing the latest innovations in cancer care to patients regardless of where they live.
Key Priorities for 2025
Thought Leadership
- Innovative Trials: Patient-centric clinical trial design such as NCI MATCHES and Leveraging cutting-edge technologies such as liquid biopsy and AI
- Regulatory Cooperation: Recommendations and public awareness campaigns to drive alignment on international trial frameworks
- Health Access: Expanding access to precision oncology in diverse global communities.
Action & Implementation
Our goal is to make early diagnosis and high-quality treatment accessible globally, ensuring no patient is left behind. That’s why we’ve established regional taskforces:
- Africa: Exploring partnerships in the continent
- Latin America: Starting with Brazil
- North America & Europe: Starting with Rural America
- Asia-Pacific: Expanding our work in China and Australia
Designed to tackle context-specific challenges and accelerate pilot projects, they bridge our Coalition’s expertise with effective implementation and aim to scale successful models from centers of excellence.
Coalition Publications
Published: 19 April 2022
NATURE MEDICINE
Reimagining Patient-Centric Cancer Clinical Trials: A Multi-Stakeholder International Coalition
This paper explores the challenges identified by the Coalition and provides a set of recommendations to serve as a blueprint for designing more patient-centric international trials.
Published: October 18, 2022
HARVARD BUSINESS REVIEW
We Need a Global System for Testing and Approving Cancer Treatments
This paper outlines that international regulatory harmonization could save 1-2 million lives each year.
Published: October 18, 2022
ASCO ABSTRACT
Global Adoption of Remote Technologies to Enable Patient-Centric Oncology Clinical Trials
This paper highlights the need to assess global adoption remote technologies and decentralized trial operations by pharmaceutical companies.
CURE4CANCER AND THE ASIA SOCIETY POLICY INSTITUTE
Enhancing Clinical Trials Access and Cooperation to Save Millions of Lives from Cancer
This report discusses global cancer trials, highlighting China’s significant cancer challenge and its role in Project Orbis to hasten cancer cure advancements through regulatory cooperation.
Published: April 12, 2024
JAMA NETWORK
Remote Monitoring and Data Collection for Decentralized Clinical Trials
This paper highlights the urgent need for greater adoption of decentralized trial technologies to make clinical trials more accessible, less burdensome, and more inclusive for underserved populations, especially in oncology.
Published: December 02, 2024
CANCER DISCOVERY
Advancing Global Health Equity in Oncology Clinical Trials Access
This report proposes solutions to overcome barriers limiting global oncology clinical trial participation, which remains under 5%, despite significant biopharmaceutical investments.
Published: November 21, 2024
CURE4CANCER AND THE ASIA SOCIETY POLICY INSTITUTE
Advancing Global Health Equity: Expanding the U.S.-Australia Cancer Alliance Toward an Asia-Pacific Collaborative Effort to Save Millions of Lives
This report highlights the U.S.-Australia partnership, grounded in an innovative concept of the hub-and-spoke network model of clinical trials and access to precision oncology, and demonstrates how collaboration may transcend borders to overcome disparities in cancer care and prevention to help patients in diverse communities.
Coalition Members
The Honorable Kevin Rudd AC
President & CEO Asia Society; 26th Prime Minister of Australia
Bob Li
SVP Global Head of Medical Affairs, Oncology AstraZenecaCo-Founder
Robert Daly
Assistant Attending/Thoracic Oncology Memorial Sloan Kettering Cancer CenterCo-Founder/ Rural America Taskforce
Julie Gralow
Chief Medical Officer (CMO) and Executive Vice President ASCO
Monica Bertagnolli
Former Director The National Institutes of Health (NIH)
Richard Pazdur
Former Director, Oncology Center of Excellence U.S. FDA
Mary Gospodarowicz
University Professor University of Toronto/Princess Margaret Cancer Center
Olufunmilayo Falusi Olopade
Walter L. Palmer Distinguished Service Professor of Medicine and Human Genetics Director, Center for Clinical Cancer Genetics and Global Health University of ChicagoAfrica Taskforce
Press
Partners
The work of the International Cancer Coalition is in collaboration with Asia Society, Memorial Sloan Kettering Cancer Center and our Research Partner, McKinsey & Company.
Research Partner:
Strategic Communication Partner:
